RPL17 and neoplasm: They mainly work by blocking the binding of PD - 1 to its ligand PD - L1, relieving the inhibitory effect of the PD - 1 pathway on T cells, thereby activating T - cell functions and enhancing the immune system’s attack on tumor cells (13–15).